ConductScience.org, home

Library / Trial comparisons

Quadrivalent (30 μg) VLP Vaccine vs Active Comparator (Fluarix): Number of Participants With at Least One Immediate Complaints

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.04280.03810.0481wilsonClinicalTrials.gov
Risk in group 20.02890.02510.0333wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.01390.007470.0204newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.481.231.78logClinicalTrials.gov
Odds ratio, group 1 over group 21.51.241.82logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Quadrivalent (30 μg) VLP Vaccine than on Active Comparator (Fluarix)71.948.9134from the risk difference intervalClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Quadrivalent (30 μg) VLP VaccineParticipants received one IM injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.2726,352OG000ClinicalTrials.gov
Group 2Active Comparator (Fluarix)Participants received one IM injection of 0.5 mL of 15 μg/strain of the Fluarix Quadrivalent® comparator vaccine on Day 0.1846,366OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With at Least One Immediate ComplaintsClinicalTrials.gov
Description
Immediate complaints were defined as any solicited local or systemic reactions. Solicited local reactions included: erythema, swelling, and pain at the injection site) and solicited systemic reactions included: fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck.
ClinicalTrials.gov
Time frame15 minutes post vaccinationClinicalTrials.gov
PopulationSAS. Participants that were non-compliant to protocol/GCP, as per investigator, were excluded from analysis.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleEfficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the ElderlyClinicalTrials.gov
NCT numberNCT03739112ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsVirus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract InfectionsClinicalTrials.gov
InterventionsQuadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator VaccineClinicalTrials.gov
Lead sponsorMedicagoClinicalTrials.gov
Results first posted2023-06-23ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT03739112?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.